Alexandra Calmy

Summary

Affiliation: St Vincent's Hospital
Country: Australia

Publications

  1. ncbi request reprint Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort
    Alexandra Calmy
    MSF, Campaign for Access to Essential Medicines, 78 rue de Lausanne, 1205 Geneva, Switzerland
    AIDS 20:1163-9. 2006
  2. ncbi request reprint Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts
    A Calmy
    HIV Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    HIV Med 8:171-80. 2007
  3. doi request reprint Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy
    A Calmy
    St Vincent s Hospital, Sydney, Australia
    HIV Med 9:101-10. 2008
  4. doi request reprint Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study
    Alexandra Calmy
    HIV, Immunology and Infectious Diseases Unit, University of New South Wales, Sydney, Australia
    J Infect Dis 200:1746-54. 2009
  5. ncbi request reprint Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection
    Handan Wand
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    AIDS 21:2445-53. 2007
  6. doi request reprint Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon
    Christian Laurent
    Institut de Recherche pour le Developpement, UMR 145 IRD University of Montpellier 1, Montpellier, France
    AIDS Res Hum Retroviruses 24:393-9. 2008
  7. doi request reprint Initial treatment for HIV infection--an embarrassment of riches
    Bernard Hirschel
    N Engl J Med 358:2170-2. 2008
  8. doi request reprint Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon
    Charles Kouanfack
    Central Hospital, Yaounde, Cameroon
    J Acquir Immune Defic Syndr 48:216-9. 2008
  9. doi request reprint Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières
    Mar Pujades-Rodriguez
    Epicentre, Paris, France
    AIDS 22:1305-12. 2008
  10. doi request reprint Monitoring of antiretroviral therapy in low-resource settings
    Stephen D Lawn
    Lancet 372:287-8; author reply 289. 2008

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort
    Alexandra Calmy
    MSF, Campaign for Access to Essential Medicines, 78 rue de Lausanne, 1205 Geneva, Switzerland
    AIDS 20:1163-9. 2006
    ..The use fixed-dose combination (FDC) is a critical tool in improving HAART. Studies on the effectiveness of combined lamivudine, stavudine and nevirapine (3TC/d4T/NVP) are scarce...
  2. ncbi request reprint Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts
    A Calmy
    HIV Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    HIV Med 8:171-80. 2007
    ..Toxicity and resistance may limit the use of HIV nucleoside reverse transcriptase inhibitors (NRTIs). We assessed the safety and activity of regimens that did not include an NRTI...
  3. doi request reprint Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy
    A Calmy
    St Vincent s Hospital, Sydney, Australia
    HIV Med 9:101-10. 2008
    ..We investigated whether metabolic and body composition parameters could predict the development of LD over 2 years in adults initiating antiretroviral therapy (ART)...
  4. doi request reprint Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study
    Alexandra Calmy
    HIV, Immunology and Infectious Diseases Unit, University of New South Wales, Sydney, Australia
    J Infect Dis 200:1746-54. 2009
    ..The role of proximal renal tubular dysfunction (PRTD) and alterations in bone metabolism in HIV-related low BMD are incompletely understood...
  5. ncbi request reprint Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection
    Handan Wand
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    AIDS 21:2445-53. 2007
    ..Metabolic syndrome (MS) identifies individuals at risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Little is known about MS and its consequences following initiation of antiretroviral therapy (ART)...
  6. doi request reprint Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon
    Christian Laurent
    Institut de Recherche pour le Developpement, UMR 145 IRD University of Montpellier 1, Montpellier, France
    AIDS Res Hum Retroviruses 24:393-9. 2008
    ..In view of stavudine toxicity, these results support recommendations calling for a gradual switch from stavudine- to zidovudine-based regimens...
  7. doi request reprint Initial treatment for HIV infection--an embarrassment of riches
    Bernard Hirschel
    N Engl J Med 358:2170-2. 2008
  8. doi request reprint Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon
    Charles Kouanfack
    Central Hospital, Yaounde, Cameroon
    J Acquir Immune Defic Syndr 48:216-9. 2008
    ..To compare adherence to antiretroviral therapy using drug level monitoring and self-report and to explore the relation between these 2 methods and viral load measurements...
  9. doi request reprint Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières
    Mar Pujades-Rodriguez
    Epicentre, Paris, France
    AIDS 22:1305-12. 2008
    ..To describe the use of second-line protease-inhibitor regimens in Médecins Sans Frontières HIV programmes, and determine switch rates, clinical outcomes, and factors associated with survival...
  10. doi request reprint Monitoring of antiretroviral therapy in low-resource settings
    Stephen D Lawn
    Lancet 372:287-8; author reply 289. 2008
  11. ncbi request reprint Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine
    Christian Laurent
    IRD, UMR 145 IRD University of Montpellier 1, Montpellier, France
    AIDS 21:768-71. 2007
    ..Virological effectiveness appeared to wane somewhat during the second year of treatment, however, and plasma nevirapine concentrations were relatively high...
  12. ncbi request reprint Treating HIV in the developing world: getting ahead of the drug development curve
    Nathan Ford
    Drug Discov Today 12:1-3. 2007
  13. ncbi request reprint HIV viral load monitoring in resource-limited regions: optional or necessary?
    Alexandra Calmy
    Medecins Sans Frontieres, Access to Medicines Campaign, Geneva, 1211, Switzerland
    Clin Infect Dis 44:128-34. 2007
    ..Rather than considering viral load data to be an unaffordable luxury, efforts should be made to ensure that viral load testing becomes affordable, simple, and easy to use in resource-limited settings...
  14. ncbi request reprint Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières
    Jean Michel Tassie
    Epicentre, Paris, France
    AIDS 17:1995-7. 2003
    ..At 6 months, outcomes were similar to those observed in western countries, and the probability of remaining on treatment was 94%. The challenge now is to extend access to HAART to the millions in urgent need...
  15. ncbi request reprint Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy
    Jean Philippe Zuber
    University and Cantonal Hospitals of Zurich, Zurich, Switzerland
    Clin Infect Dis 38:1178-85. 2004
    ..7 years. HAART significantly decreased mortality due to PAHRH as well as other causes. This study suggests a beneficial effect of combination ART in patients with PAHRH...
  16. ncbi request reprint HIV drug resistance
    Alexandra Calmy
    N Engl J Med 350:2720-1. 2004
  17. ncbi request reprint Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial
    Christian Laurent
    Institut de Recherche pour le Développement and Department of International Health, University of Montpellier UMR 145, Montpellier, France
    Lancet 364:29-34. 2004
    ..We aimed to assess these issues for one of the most frequently prescribed treatments in Africa, a generic fixed-dose combination of nevirapine, stavudine, and lamivudine...
  18. ncbi request reprint First-line and second-line antiretroviral therapy
    Alexandra Calmy
    Lancet 364:329; author reply 330. 2004
  19. ncbi request reprint Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine
    Milos Opravil
    AIDS 18:2213-5. 2004
  20. ncbi request reprint Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up
    Alexandra Calmy
    AIDS 18:2353-60. 2004
  21. ncbi request reprint Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon
    Anke Bourgeois
    Institut de Recherche pour le Développement and Department of International Health, University of Montpellier UMR 145, Montpellier, France
    Antivir Ther 10:335-41. 2005
    ..To assess the effectiveness of generic anti-retroviral drugs in terms of survival and virological and immunological responses, as well as their tolerability and the emergence of viral resistance...
  22. pmc Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006
    Florence Damond
    APHP, Hopital Bichat Claude Bernard, Laboratoire de Virologie, Paris, 75018 France
    J Clin Microbiol 46:2088-91. 2008
    ..Quantification varied between laboratories, and international standardization of quantification assays is strongly needed...
  23. doi request reprint How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals
    Jens Van Roey
    Medecins Sans Frontieres, Campaign for Access to Essential Medecins, Rue de Lausanne 78, 1211 Geneva, Switzerland
    Drug Discov Today 13:601-5. 2008
    ..Key research questions relevant for developing countries need to be answered early in the drug development process to ensure maximum benefit for the majority...
  24. ncbi request reprint Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy
    Alexandra Calmy
    Division of aInfectious Diseases, Hopital Cantonal Universitaire, Geneva, Switzerland
    AIDS 17:770-2. 2003